R115866

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP870093235
CAS870093-23-5
Structure
MDL NumberMFCD13194908
Molecular Weight377.51
Description≥98% (HPLC)
SolubilityDMSO: 2 mg/mL, clear
Assay≥98% (HPLC)
Colorcolorless
Formfilm
Size5MG, 25MG
Storage Conditions2-8°C

1Oral R115866 in the Treatment of Moderate to Severe Facial Acne Vulgaris: An Exploratory Study

C J Verfaille, M Coel, I H Boersma, J Mertens, M Borgers, D Roseeuw

Br J Dermatol. 2007 Jul;157(1):122-6.

PMID: 17459036

Read More

1Oral R115866 in the Treatment of Moderate to Severe Plaque-Type Psoriasis

C J Verfaille, C A C B Thissen, H J Bovenschen, J Mertens, P M Steijlen, P C M van de Kerkhof

J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1038-46.

PMID: 17714122

Read More

1R115866 Inhibits All-Trans-Retinoic Acid Metabolism and Exerts Retinoidal Effects in Rodents

P Stoppie, M Borgers, P Borghgraef, L Dillen, J Goossens, G Sanz, H Szel, C Van Hove, G Van Nyen, G Nobels, H Vanden Bossche, M Venet, G Willemsens, J Van Wauwe

J Pharmacol Exp Ther. 2000 Apr;293(1):304-12.

PMID: 10734183

Read More

1The CYP26 Inhibitor R115866 Potentiates the Effects of All-Trans Retinoic Acid on Cultured Human Epidermal Keratinocytes

S Giltaire, F Herphelin, A Frankart, M Hérin, P Stoppie, Y Poumay

Br J Dermatol. 2009 Mar;160(3):505-13.

PMID: 19120344

Read More

1Topical Treatment With CYP26 Inhibitor Talarozole (R115866) Dose Dependently Alters the Expression of Retinoid-Regulated Genes in Normal Human Epidermis

E Pavez Loriè, M Cools, M Borgers, L Wouters, B Shroot, E Hagforsen, H Törmä, A Vahlquist

Br J Dermatol. 2009 Jan;160(1):26-36.

PMID: 19016711

Read More

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

Follow us on

Copyright © 2022 Alfa Chemistry. All rights reserved.